Angiotensin (Ang) II stimulates plasminogen activator inhibitor-1 (PAI-1) expression in many cell types by mechanisms that are cell-type specific. We measured effects of Ang II or norepinephrine on PAI-1 expression in wild type (WT) and Ang type-1a receptor knockout mice (AT 1a À/À) in the presence or absence of the non-specific AT 1 antagonist losartan. Ang II and norepinephrine increased systolic blood pressure equally, whereas losartan decreased the pressor response of the former but not the latter in WT mice. In AT 1a À/À mice, baseline systolic blood pressure was lower with no effect of Ang II, norepinephrine, or losartan. Ang II stimulated PAI-1 expression in the heart, aorta, and kidney and markedly in the liver of WT mice. In AT 1a À/À mice, Ang II-stimulated PAI-1 was significantly attenuated compared with the WT in the heart and aorta but significantly enhanced in the kidney. Losartan decreased the induction in the aorta and liver of WT, and in the kidney and liver of AT 1a À/À mice. Norepinephrine increased PAI-1 expression in WT heart and aorta, and in AT 1a À/À heart, kidney, and liver with no effect of losartan. Renal PAI-1 expression correlated with AT 1b receptor mRNA. We conclude that Ang II stimulates PAI-1 expression in part through the AT 1b receptor in the kidney and liver. Further, norepinephrine induces PAI-1 expression in vivo with AT 1a receptor deficiency modulating the effect. 72 Kidney International (2007) 72, 72-81 Plasma aldosterone concentrations are given in pg/ml. *Po0.05 versus wild type Ang II, w Po0.05 versus wild type Ang II, z Po0.05 versus wild type norepinephrine. Kidney International (2007) 72, 72-81 73 NJ Brown et al.: AT 1 receptor and PAI-1 o r i g i n a l a r t i c l e
Activation of the renin-angiotensin-aldosterone system causes vascular toxicity in part through effects of angiotensin (Ang) II to induce the expression of plasminogen activator inhibitor-1 (PAI-1), 1,2 a major physiological inhibitor of fibrinolysis, in vitro and in vivo. 3 Increased PAI-1 has been implicated in the pathogenesis of coronary arterial thrombosis and myocardial infarction in mouse models 4 and with increased risk of atherosclerotic thrombotic events in studies in humans. 5, 6 In addition, by preventing the activation of matrix metalloproteinases and the degradation of extracellular proteins by plasmin, PAI-1 promotes fibrosis. [7] [8] [9] [10] In the kidney, increased PAI-1 expression contributes to the pathogenesis of both glomerular injury and tubulointerstitial fibrosis. 9, 11, 12 Ang II stimulates PAI-1 expression in vitro in a variety of cell types including adipocytes, astrocytes, endothelial cells, vascular smooth muscle cells (VSMCs), proximal tubular epithelial cells, and mesangial cells. 1, 2, [13] [14] [15] The mechanism through which Ang II stimulates PAI-1 expression depends on the cell type. For example, in endothelial cells and proximal tubular epithelial cells, the effect of Ang II on PAI-1 expression appears to be at least partially mediated through its hexapeptide metabolite angiotensin-3-8 (Ang IV). 14, 16, 17 Thus, administration of pharmacological agents that block the conversion of Ang II to Ang IV prevents the effect of Ang II on PAI-1 expression. Similarly, Ang II-induced endothelial PAI-1 expression is blocked by AT 4 receptor antagonists, but not by selective AT 1 or AT 2 receptor antagonists. 16 In contrast, AT 1 receptor antagonism decreases PAI-1 expression in astrocytes, VSMCs, and adipocytes. 2, 13, 15 Studies in the rat provide conflicting data as to whether Ang II increases cardiovascular and renal PAI-1 expression in vivo through the AT 1 receptor or via conversion of Ang II to Ang IV and activation of the AT 4 receptor. We have reported previously that AT 1 receptor antagonism abolished acute Ang II-induced hepatic, renal, aortic, and cardiac PAI-1 expression. 18 Likewise, AT 1 receptor antagonism decreased Ang II-induced aortic and cardiac PAI-1 expression in Sprague-Dawley rats. 19 On the other hand, 2-week infusion of either Ang II or Ang IV significantly increased cardiac PAI-1 expression, whereas only Ang II increased renal PAI-1 expression. 20 However, none of these studies delineated the role of specific AT 1 receptor subtypes in Ang II-stimulated PAI-1 expression.
We therefore tested the hypothesis that Ang II induces PAI-1 expression via the AT 1a receptor in vivo. To do this, we compared the effect of a 4-h infusion of Ang II or an equivalent pressor dose of norepinephrine on cardiac, aortic, renal, and hepatic PAI-1 expression in wild type (WT) mice and in mice lacking the AT 1a receptor (AT 1a À/À), in the presence and absence of the non-specific AT 1 receptor antagonist losartan. Figure 1 illustrates the effect of Ang II or norepinephrine on systolic blood pressure (SBP) in WT and AT 1a À/À mice. Ang II (mean SBP over 4 h 125.975.2 mm Hg, P ¼ 0.004 versus saline) or norepinephrine (mean SBP 127.074.4 mm Hg, P ¼ 0.002) significantly increased pressure compared with normal saline (mean SBP 103.075.5 mm Hg) in the WT mice. The pressor effects of Ang II and norepinephrine were similar (P ¼ 0.877). Pre-treatment with losartan significantly decreased baseline SBP (Figure 1 , P ¼ 0.002) and attenuated the SBP response to Ang II (mean SBP 108.877.4 mm Hg, P ¼ 0.030 versus Ang II alone during first 3 h, P ¼ 0.530 versus saline) in WT mice. There was no effect of losartan on the pressor response to norepinephrine (mean SBP during norepinephrine and losartan 125.377.4 mm Hg). Baseline SBP was significantly lower in AT 1a À/À mice compared to WT (Figure 1 , Po0.001).
RESULTS

Hemodynamic and aldosterone responses to agonists
Moreover, there was no effect of either Ang II (P ¼ 0.778) or norepinephrine (P ¼ 0.648) on SBP in AT 1a À/À mice. Pre-treatment with losartan abolished the difference in baseline SBP between WT and AT 1a À/À mice (P ¼ 0.890); there was no effect of losartan on SBP during Ang II or norepinephrine in AT 1a À/À mice. Table 1 shows the effect of treatment on plasma aldosterone concentrations in WT and AT 1a À/À mice. Ang II only numerically tended to increase aldosterone in WT mice. However, aldosterone concentrations were significantly higher in Ang II-infused WT mice compared with Ang IIinfused AT 1a À/À mice. In addition, losartan significantly decreased aldosterone concentrations in Ang II-and norepinephrine-infused WT mice, but did not significantly affect aldosterone concentrations in AT 1a À/À mice.
PAI-1 mRNA expression and active PAI-1 antigen
Ang II increased PAI-1 expression in heart (9.9-fold, Po0.001 versus saline), aorta (4.6-fold, Po0.05), kidney (2.5-fold, Po0.05), and liver (97-fold, Po0.001), respectively, of WT mice ( Figure 2 ). Losartan attenuated Ang IIinduced PAI-1 expression in the aorta (1.8-fold, NS versus saline) and liver (9.8-fold, Po0.01 versus Ang II alone). In AT 1a À/À mice, Ang II-induced PAI-1 expression was diminished in the heart (Po0.05 versus WT Ang II) and aorta (Po0.05 versus WT Ang II), equivalent in the liver (43fold versus WT saline), but enhanced in kidney (9.1-fold versus WT saline, Po0.05 versus WT Ang II) compared with WT mice. Losartan attenuated Ang II-induced PAI-1 expression in the kidney (1.6-fold versus WT saline, Po0.05 versus Ang II alone) and liver (11.9-fold, Po0.05 versus Ang II alone) of AT 1a À/À mice.
To determine whether the effect of Ang II on PAI-1 expression was pressor-dependent, we assessed whether norepinephrine increased PAI-1 expression in WT or AT 1a À/À mice. Norepinephrine increased PAI-1 expression in the heart (15.6-fold) and aorta (7.4-fold) but not the kidney or liver of WT mice. Even though norepinephrine did not increase blood pressure, norepinephrine increased PAI-1 expression in heart (8.2-fold versus WT saline, Po0.001), kidney (7.7-fold, Po0.01), and liver (50.9-fold, Po0.001) in AT 1a À/À mice. Losartan did not affect norepinephrine induced PAI-1 expression. To determine whether norepinephrine induced PAI-1 mRNA expression via an effect on TGF-b expression, we measured TGF-b mRNA expression in Figure 1 | Systolic blood pressure (SBP) response to treatment in WT and AT 1a À/À mice. Infusion of either angiotensin II (Ang II, P ¼ 0.004) or norepinephrine (P ¼ 0.002) significantly increased SBP compared with normal saline in the WT mice. The pressor effects of Ang II and norepinephrine were similar in WT mice (P ¼ 0.877). Losartan blunted the pressor effect of Ang II, but not norepinephrine. Baseline blood pressure was significantly lower in AT 1a À/À mice compared to WT mice. There was no effect of losartan, Ang II, or norepinephrine on SBP in the AT 1a À/À mice. the heart, kidney, and liver ( Table 2 ). Norepinephrine did not increase TGF-b expression in any organ in WT or AT 1a À/À mice. TGF-b expression was similar in the heart of WT and AT 1a À/À mice. TGF-b expression was decreased in the liver of AT 1a À/À mice compared with WT mice, regardless of treatment. On the other hand, renal TGF-b expression was increased in saline-treated and norepinephrine þ losartantreated AT 1a À/À mice compared with WT mice. Renal TGF-b mRNA expression correlated with renal PAI-1 expression in AT 1a À/À mice (r ¼ 0.783, Po0.001), but not in WT mice (r ¼ 0.194, P ¼ 0.441). However, there was no relationship between relative renal pSmad2 protein, a marker of TGF-b signaling, and renal PAI-1 expression (P ¼ 0.582). Ang II also significantly increased circulating active plasma PAI-1 antigen in WT and AT 1a À/À mice and losartan prevented this effect ( Figure 3 ). Norepinephrine significantly increased interleukin (IL)-6 and active PAI-1 antigen in AT 1a À/À mice, but not in WT mice. Circulating active plasma PAI-1 antigen concentrations correlated with renal (r ¼ 0.904, Po0.001) and hepatic (r ¼ 0.731, Figure 2 | Effect of saline, Ang II, and norepinephrine (NE) infusions on PAI-1 expression as measured by RT-PCR in heart, aorta, kidney, and liver of WT and AT 1a À/À mice. *Po0.01 versus WT saline, w Pp0.001 versus WT saline, z Po0.05 versus AT 1a À/À saline, y Pp0.05 versus the same treatment in WT, || Pp0.001 versus AT 1a À/À saline, z Po0.05 versus WT saline, # Po0.01 versus AT 1a À/À saline, **Po0.05 versus AT 1a À/À Ang II, ww Po0.01 versus same treatment in WT, zz Po0.01 versus WT Ang II. Po0.001) PAI-1 expression. In addition, IL-6 (r ¼ 0.632, P ¼ 0.006) and active PAI-1 antigen (r ¼ 0.666, P ¼ 0.003) correlated with plasma aldosterone concentrations in AT 1a À/À mice, but not in WT mice. After controlling for losartan treatment, PAI-1 mRNA expression in the kidney of AT 1a À/À mice also correlated significantly with circulating aldosterone (r ¼ 0.433, P ¼ 0.04). There was no correlation between renal PAI-1 expression and aldosterone in WT mice. There was no correlation between cardiac, hepatic, or aortic PAI-1 mRNA expression and aldosterone in either strain.
AT 1a and AT 1b receptor expression
To determine whether differences in patterns of PAI-1 mRNA expression in the kidney and liver of WT and AT 1a À/À mice resulted from differences in expression of the AT 1b receptor, we measured AT 1a and AT 1b receptor mRNA expression. In WT mice, Ang II decreased AT 1a receptor expression in the kidney and liver, even during losartan (Table 3) . Norepinephrine alone also decreased AT 1a receptor expression in WT mice. As expected, AT 1a receptor mRNA expression was reduced to artifactual levels in the AT 1a À/À mice. Renal and hepatic AT 1b receptor expression was statistically similar in WT and AT 1a À/À mice. However, the relationship between AT 1b receptor and PAI-1 mRNA expression differed in the kidneys of WT and AT 1a À/À mice. Thus, while renal PAI-1 mRNA expression correlated with AT 1b receptor expression in both WT (r ¼ 0.767, Po0.001) and AT 1a À/À (r ¼ 0.514, P ¼ 0.020) mice, the slope of the relationship was significantly steeper in the AT 1a À/À mice (slope 6.8 versus 0.5, Po0.001). Hepatic PAI-1 expression did not correlate with AT 1a or AT 1b receptor expression in WT or AT 1a À/À mice.
Localization of PAI-1 expression by in situ hybridization
Figures 4 and 5 show the effect of saline, Ang II, and norepinephrine on PAI-1 mRNA signal in the heart and aorta from WT and AT 1a À/À mice. Hybridization with control sense probes showed no specific signal. There was minimal expression of PAI-1 mRNA in cardiac myocytes and aorta by in situ hybridization in saline-infused WT or AT 1a À/À mice. In Ang II-treated WT mice, PAI-1 mRNA signal was increased (2-3 þ ) in the myocytes of the left ventricle and septum as well as in aortic smooth muscle cells (2-3 þ ) and aortic endothelium (1 þ ). In contrast, in AT 1a À/À mice, Ang II infusion induced a variable, but overall modest (1-3 þ ) increase in PAI-1 expression in the endocardium, but not in ventricular myocytes. Only trace PAI-1 mRNA signal was observed in aortae from Ang II-infused AT 1a À/À mice. Infusion of norepinephrine induced a strong (3-4 þ ) increase in PAI-1 mRNA signal in the myocytes of the left ventricle, a 1 þ increase in signal in the myocytes of the right ventricle, and a 1-2 þ increase in PAI-1 mRNA signal in the endocardium of hearts from WT mice; there was also a 1-2 þ increase in PAI-1 mRNA signal in the vascular smooth muscle and endothelium of the aorta. Norepinephrine induced a 2 þ increase in PAI-1 mRNA signal in the endocardium of AT 1a À/À mice, with focal areas of increased PAI-1 mRNA signal in the left ventricle, with only trace signal in the aorta. Figure 3 | Effect of saline, Ang II, and norepinephrine (NE) infusions on plasma PAI-1 (left) and IL-6 (right) concentrations. *Po0.05 versus WT saline, w Po0.005 versus WT saline, z Po0.01 versus WT NE, y Po0.05 versus WT NE þ losartan, || Po0.05 versus any WT group, z Po0.05 versus AT 1a À/À Ang II losartan. Figure 6 shows the effect of saline, Ang II, and norepinephrine on PAI-1 mRNA expression in the kidney from WT and AT 1a À/À mice. During saline infusion, there was strong PAI-1 expression in the glomeruli of AT 1a À/À, but not WT, mice. Ang II induced mild diffuse expression of PAI-1 in the kidney of both WT and AT 1a À/À mice with 2 þ increase in signal in the mesangium of AT 1a À/À animals. Norepinephrine induced strong signal in the main renal There was minimal PAI-1 expression in the aorta in saline-infused WT mice (a) or AT 1a À/À mice (e). Ang II stimulated a marked increase in PAI-1 expression in aortic VSMCs and a modest increase in aortic endothelium in WT mice (b). This was attenuated by pretreatment with losartan (c). Norepinephrine induced strong PAI-1 expression in aortic vascular smooth muscle and endothelium of WT mice (d). Only trace PAI-1 aortic signal was observed in Ang II-treated (f) or norepinephrine-treated (g) AT 1a À/À mice.
artery and its major branches in both WT and AT 1a À/À, whereas norepinephrine also increased PAI-1 focally in peritubular capillaries in the AT 1a À/À animals. Following saline, the liver (not shown) of both WT and AT 1a À/À mice showed similar very low-level diffuse PAI-1 signal. Ang II and norepinephrine induced intense signal in centrilobular hepatocytes in both WT and AT 1a À/À mice.
DISCUSSION
To test the hypothesis that Ang II stimulates PAI-1 expression via the AT 1a receptor in vivo, we studied the effect of genetic AT 1a deficiency and pharmacological AT 1 receptor blockade on PAI-1 expression. The data suggest that Ang II regulates PAI-1 expression in the heart and aorta primarily via the AT 1a receptor, whereas the AT 1b receptor contributes significantly to Ang II-stimulated PAI-1 expression in the kidney and liver. In addition, this study provides the first evidence that norepinephrine regulates tissue PAI-1 expression in vivo. AT 1a receptor deficiency was associated with decreased basal PAI-1 expression in the heart and aorta, but not in the kidney or liver. These data concur with the data of Tsujino et al., 21 who reported that the effect of AT 1a deficiency on circadian PAI-1 expression differs in an organ-specific fashion. In that study, the investigators found depressed trough PAI-1 expression in the heart and a lack of circadian variation in PAI-1 expression in the aorta of AT 1a À/À mice, whereas hepatic PAI-1 expression continued to exhibit circadian rhythm and there was no difference in PAI-1 expression in the kidney of AT 1a À/À versus WT mice.
Previous studies using pharmacological receptor antagonists have consistently demonstrated that Ang II induces PAI-1 expression in vitro in cardiomyocytes 22 and VSMCs 22, 23 and in vivo 18, 20, 22 in the heart and aorta via its AT 1 receptor. A recent study in cultured VSMCs from AT 1a À/À suggests that Ang IV also induces PAI-1 expression in VSMCs. In this study, Ang II-induced cardiac and aortic PAI-1 expression was dramatically attenuated in AT 1a À/À mice, indicating that the AT 1a receptor primarily mediates increased cardiac and aortic PAI-1 expression in this in vivo model. 24 In contrast, the finding in kidney and liver that Ang II-induced PAI-1 There was no effect of saline treatment on PAI-1 signal in WT mice (a). (b) Ang II induced mild diffuse expression in WT mice, (c) which was similar during losartan treatment. (d) There was no effect of norepinephrine (e) or norepinephrine þ losartan on PAI-1 signal in WT mice. (f) PAI-1 signal was mildly and diffusely increased in saline-treated AT 1a À/À mice compared with (k) untreated, age-matched WT control. (g) Ang II induced PAI-1 expression in the mesangium of AT 1a À/À mice (h) and this was attenuated after losartan. (i) Norepinephrine induced PAI-1 signal in the mesangium and peritubular capillaries in AT 1a À/À mice, (j) even in the presence of losartan.
expression was increased or preserved in AT 1a À/À mice and that pharmacological AT 1 receptor antagonism abolished this expression indicates that the AT 1b receptor contributes to the regulation of PAI-1 expression in these organs. Indeed, the relationship between PAI-1 and AT 1b receptor mRNA expression was enhanced in AT 1a À/À compared with WT mice. In addition, the localization of PAI-1 signal to peritubular capillaries in the norepinephrine-treated AT 1a À/À mice is in proximity to the tubular localization of AT 1b receptors by immunohistochemistry. 25 These findings are compatible with prior data indicating that non-specific pharmacological AT 1 receptor antagonism 18 decreases PAI-1 expression in these organs.
We also report that norepinephrine-induced PAI-1 expression in the heart and aorta of WT mice and the heart of AT 1a À/À mice. Of note, AT 1a deficiency unmasked an effect of norepinephrine on PAI-1 expression in the kidney and liver, while at the same time the pressor response to norepinephrine was blunted. This study did not specifically address the mechanism through which norepinephrine increases PAI-1 expression. Norepinephrine increases cardiomyocyte expression of TGF-b in male Sprague-Dawley rats 26 and enhances the effect of TGF-b on PAI-1 expression in cardiac fibroblasts; 27 however, we did not find a stimulatory effect of acute (4 h) Ang II or norepinephrine on TGF-b expression in any organ in either WT or AT 1a À/À mice. Although constitutive TGF-b mRNA expression was increased in the kidney of AT 1a À/À mice compared with WT mice and renal PAI-1 expression correlated with TGF-b expression, the lack of correlation between PSmad2, a downstream marker of TGF-b activation, and renal PAI-1 expression, suggests that increased TGF-b expression did not account for norepinephrine-induced PAI-1 expression in the AT 1a À/À mice.
Interruption of the renin-angiotensin-aldosterone system reduces interstitial fibrosis and glomerulosclerosis. 28, 29 Prior studies indicate that Ang II induces PAI-1 expression in the heart and kidney in part through effects on endogenous aldosterone and that mineralocorticoid receptor antagonism can cause regression of existing glomerulosclerosis. [30] [31] [32] In this study, aldosterone concentrations were preserved in vehicle and norepinephrine-treated AT 1a À/À mice. This is consistent with data indicating that aldosterone synthesis may occur via AT 1b receptor stimulation, as well as via Ang II-independent pathways, in AT 1a À/À mice. 33, 34 Increased aldosterone concentrations were associated with increased inflammation as measured by the cytokine IL-6. The correlation between PAI-1 antigen concentrations or renal PAI-1 mRNA expression and aldosterone suggests that endogenous aldosterone contributed to PAI-1 expression in AT 1a À/À mice. Given the profibrotic effects of PAI-1, this finding is particularly intriguing in the context of recent studies implicating aldosterone in cardiovascular remodeling in AT 1a -deficient mice. For example, Katada et al. 34 have reported that endogenous aldosterone contributes to fibrosis following myocardial infarction in AT 1a À/À mice. In an as yet unpublished study, Kagayami et al. (abstract, Hypertension 2006) have observed that AT 1a À/À mice demonstrate increased sensitivity to aldosterone/salt-induced cardiac fibrosis.
To assess the pressor-dependence of Ang II-stimulated PAI-1 expression, we determined the effect of equivalent pressor doses of Ang II and norepinephrine on PAI-1 expression in WT mice. Unexpectedly, AT 1a À/À mice were protected against the pressor effects of both norepinephrine and Ang II. The renin-angiotensin-aldosterone system and sympathetic system interact at many levels. Ang II facilitates norepinephrine release at nerve endings 35 and also increases expression of the norepinephrine transporter through its AT 1 receptor. 36 In addition, crosstalk between the AT 1 and a 1adrenergic receptors and between AT 1 and b-adrenergic receptors has been described in rat and mouse cardiomyocytes and in vivo. 37, 38 Prior studies in pithed rats indicate that pharmacological AT 1 receptor antagonism reduces the pressor response to norepinephrine. 39, 40 More recently, Raasch et al. 41 reported that AT 1 receptor antagonism decreased vascular sensitivity to norepinephrine via a mechanism involving both neuronal norepinephrine uptake and presynaptic a 2 -mediated autoinhibition. To our knowledge, this study is the first to demonstrate an attenuated pressor response to norepinephrine in AT 1a receptor-deficient mice.
In summary, this study provides new evidence for tissuedependent roles of the AT 1a and AT 1b receptors in regulating Ang II-stimulated PAI-1 expression in vivo. Ang II stimulates PAI-1 expression primarily via the AT 1a receptor in the heart and the aorta, but via the AT 1b receptor in the kidney and liver. The study provides novel data supporting physiological interaction between the renin-angiotensin-aldosterone system and adrenergic system in regulating vascular tone and PAI-1 expression. Norepinephrine-induced PAI-1 expression could contribute to the variable effect of AT 1 receptor antagonism on PAI-1 concentrations observed in clinical studies. 42, 43 MATERIALS AND METHODS WT C57BL/6 and homozygous AT 1a À/À mice bred on a C57BL/6 background were studied. In a first experiment, 8-week-old male AT 1a À/À mice were offspring of AT 1a þ /À mice maintained at Vanderbilt since 1995. Twelve WT and 12 AT 1a À/À mice were randomized to each of three treatment groups (n ¼ 4 each): intravenous saline, intravenous Ang II, and intravenous norepinephrine. The experiment was repeated in the presence or absence of the AT 1 receptor antagonist losartan. In this latter experiment, AT 1a À/À mice were obtained from the Jackson Laboratory (B6.129P2-Agtr1 tm1UNC /J; Bar Harbor, ME, USA). Twenty-five male WT and 25 AT 1a À/À mice were randomized to treatment arms (n ¼ 5 each): intravenous saline, intravenous Ang II, oral losartan þ intravenous Ang II, intravenous norepinephrine, and oral losartan þ intravenous norepinephrine. All animal procedures were approved by the Vanderbilt University Institutional Animal Care and Use Committee.
Mice were anesthetized, and silicone and polyethylene cannulae were placed in the jugular vein and carotid artery for continuous infusion and monitoring of arterial blood pressure, respectively. These cannulae were passed under the skin and out through the nape and fixed with sutures. Mice were allowed to recover and infusion catheters were flushed every other day with physiological saline containing 200 IU heparin/ml and 1 mg ampicillin/ml. Animals randomized to losartan were given losartan in the drinking water (1 mg/ml) beginning after catheter placement. Infusion studies were performed 3 days postcatheter placement. Agonists or saline were infused through the venous catheter for 4 h at a rate of 1.375 ml/min. Ang II was infused at a dose of 600 ng/kg/min, a dose previously shown to increase PAI-1 expression in the rat and mouse. 18, 44 Norepinephrine was infused at 12 mg/kg/min, a dose chosen to cause a pressor response similar to that seen with Ang II. Blood pressure was measured via carotid artery catheter throughout infusions. Mice were killed immediately after the 4-h infusion and the aorta, heart, liver, and kidney were harvested. Tissues for in situ hybridization were immersion-fixed in 4% paraformaldehyde-phosphate-buffered saline solution. The remainder of the heart, aorta, kidney, and liver was frozen immediately in liquid nitrogen (LN 2 ) and stored at 801C until mRNA analysis. Aortae were collected into RNAlater s solution (Ambion, Austin, TX, USA), stored at 41C overnight, and then transferred to a vial for storage at À801C until assay.
Biochemical assays
Aldosterone was determined using a radioimmunoassay utilizing 125 I-aldosterone (MP Biomedicals, Irvine CA, USA), a primary antibody to aldosterone (NIDDK National Hormone & Peptide Program, Torrance, CA, USA), and a secondary anti-rabbit gglobulin antibody (Linco Research, St Charles, MO, USA). Active murine plasma PAI-1 (Molecular Innovations, Southfield, MI, USA) and plasma IL-6 (R&D Systems Inc., Minneapolis, MN, USA) were measured using commercially available enzyme-linked immunosorbent assay kits.
Oligonucleotide primers for reverse transcription-polymerase chain reaction (RT-PCR) Oligonucleotide primers were designed to complement mRNA sequences reported in the GenBank database (murine PAI-1 [forward (5 0 -TCCTCATCCTGCCTAAGTTCTC), reverse (5 0 -GTGC CGCTCTCGTTTACCTC)), TGF-b 1 (forward (5 0 -GCAACATGTGG AACTCTACCAG), reverse (5 0 -GACGTCAAAAGACAGCCACTCA)), AT 1a R (forward (5 0 -TTTCCAGATCAAGTGCATTTTGA), reverse (5 0 -AGAGTTAAGGGCCATTTTGCTTT)); AT 1b (forward (5 0 -ACTG GCAGAAATACCATGTCTTCA), reverse (5 0 -CCGACTAATTATGTT CATGTGGAAA)), and glyceraldehyde-3-phosphate dehydrogenase (forward (TGAGGCCGGTGCTGAGTATGTCG) and reverse (CCAC AGTCTTCTGGGTGGCAGTG-3 0 )). For initial verification of these products, one sample of each amplicon was sequenced by cycle sequencing using dye terminators (BigDye Terminators, Perkin-Elmer Applied Biosystems, Waltham, MA, USA) on an ABI Prism 310 Genetic Analyzer (Perkin-Elmer Applied Biosystems). The specificity of all subsequent reactions was verified by first-derivative melting curve analysis.
Quantitative RT-PCR Relative quantification of mRNA was done by one-step RT-PCR with real-time amplicon detection with the fluorescent dye SYBR Green I on a LightCycler Instrument (Roche Applied Science, Indianapolis, IN, USA), as described previously. 44 RT-PCR was performed in a reaction volume of 20 ml with 500 nmol/l each primer for a series of twofold template dilutions from 1:1 to 1:16, corresponding to 10.0-0.625 mg/l total RNA. For reaction buffer and RT-PCR enzymes, the LightCycler RNA Amplification Kit SYBR Green I (Roche Applied Science) was used. After reverse transcription at 551C for 10 min and an initial denaturation step at 951C for 30 s, amplification was performed with 50 cycles of denaturation (951C for 1 s), annealing (631C for 10 s), and extension (721C for 20 s). To monitor amplification in real-time, double-strand DNAdependent SYBR Green I fluorescence was measured at the end of the extension period of each cycle. For each transcript, an inverse correlation was observed between the amount of applied total RNA and the interpolated cycle number (C) at which the magnitude of fluorescence increased with maximum velocity. The slope (m) and y intercept (b) defining this relationship were calculated by linear regression on the equation C ¼ m Â log (g total RNA) þ b, with excellent goodness of fit (R 2 40.98) obtained for all dilution series. The average ratio of PAI-1 (or other gene of interest)/glyceraldehyde-3-phosphate dehydrogenase transcript observed in samples obtained from each mouse was normalized to the average ratio of the transcript observed in samples obtained from saline-treated WT mice.
In situ hybridization 35 S-labeled sense and antisense riboprobes for PAI-1 were prepared by transcription of the pCR TM II plasmid with insertion of the cDNA fragment by SP6 or T7 RNA polymerase (Promega, Madison, WI, USA). Sections were dewaxed in xylene and hydrated in graded ethanols and then phosphate-buffered saline. After treatment by proteinase K and triethanolamine/acetic anhydride, sections were dehydrated in ethanol and air-dried. Hybridization was done in buffer (40% formamide, 10% dextran sulfate, 8 mmol/l dithiothreitol, 0.2 mg/ml tRNA, 300 mmol/l NaCl, 10 mmol/l Tris-HCl, 5 mmol/l ethylenediaminetetraacetic acid, 0.02% polyvinylpyrolidone, 0.02% Ficoll, and 0.02% bovine serum albumin) overnight at 501C. Sections were washed in 5 Â SSC, 20 mmol/l b-mercaptoethanol at 501C for 15 min, in 2 Â SSC, 50% formamide at 651C for 20 min, in 0.1 M Tris-Hcl (pH 8.0), 0.01 M EDTA, 0.1 M Nacl (TEN) twice at 371C for 10 min, treated with RNase at 371C for 30 min, washed in TEN at 371C for 10 min, in 2 Â SSC and 0.1 Â SSC each twice at 651C for 15 min. Sections were then dehydrated in ethanol and air-dried, dipped in photographic emulsion, and exposed at 41C for 14 days. The sections were developed with D-19 developer (Eastman Kodak, Rochester, NY, USA) and counterstained with Toluidine Blue. In situ expression was examined without knowledge of the treatment group assignments, and overall intensity of signal was semiquantitatively scored on a 0-3 þ scale, where 0 is no significant expression, 1 þ is mild signal, 2 þ is moderate signal, and 3 þ is intense signal. Localization of signal was also evaluated.
Western blotting for phospho-Smad 2 Frozen kidney tissues were homogenized in radioimmunoprecipitation buffer (Boston BioProducts, Worcester, MA, USA) containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM ethylenediamine tetraacetic acid, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM phenylmethyl sulfonyl fluoride, phosphatase inhibitor cocktail 1 and 2 (Sigma, St Louis, MO, USA), and proteinase inhibitor cocktail tablet (Roche Applied Science) on ice. The protein concentration was measured using the BCA TM Protein Assay kit (Pierce, Rockford, IL, USA). Sample protein (80 mg) were loaded and separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred into a 0.2-mm nitrocellulose membrane. Phospho-Smad-(pSmad)2 was detected with a specific rabbit anti-PSmad2 polyclonal antibody (Upstate Technology, Charlotte, VA, USA) at 1:500 dilution, and a-tubulin was detected by monoclonal anti-a-tubulin antibody at 1:10 000 dilution (Abcam, Cambridge, MA, USA) overnight at 41C. Secondary antibody was added after washing and incubated at room temperature for 1 h. Protein bands on Western blots were visualized by ECL Plus TM (GE Healthcare, Piscataway, NJ, USA) and exposure to imaging film (Eastman Kodak). Expression of PSmad2 was quantified as the ratio of specific staining to a-tubulin.
Statistics analysis
Data are presented as means7s.e.m. Because responses to Ang II and norepinephrine were statistically similar in the two experiments, data from the experiments were combined for analysis. The effect of treatment on SBP was analyzed using a general linear model in which the within-subjects factor was time and the between-subjects factors were mouse strain and treatment. Results were confirmed using non-parametric methods. Comparisons of the ratios of PAI-1 (AT 1a receptor, AT 1b receptor, or TGF-b)/glyceraldehyde-3-phosphate dehydrogenase transcript among and between groups were made using a Kruskal-Wallis or Mann-Whitney test, as appropriate. A Po0.05 was considered significant.
